Halozyme to Host Investor Conference Call to Provide Updated 2025 Financial Guidance
Halozyme Therapeutics (NASDAQ: HALO) has announced an upcoming Investor Conference Call scheduled for Wednesday, January 8, 2025, at 5:30 a.m. PT / 8:30 a.m. ET. During this call, Dr. Helen Torley, President and CEO, and Nicole LaBrosse, CFO, will present preliminary unaudited results for the full year 2024 and provide updated financial guidance for 2025 and beyond.
Investors can pre-register for the live call through a provided registration link. The presentation will also be accessible via webcast through the 'Investors' section of Halozyme's website, with presentation materials becoming available 15 minutes before the call. A recording of the call will be made available afterward.
Halozyme Therapeutics (NASDAQ: HALO) ha annunciato una prossima conference call per gli investitori programmata per mercoledì 8 gennaio 2025, alle 5:30 PT / 8:30 ET. Durante questa chiamata, Dr. Helen Torley, Presidente e CEO, e Nicole LaBrosse, CFO, presenteranno i risultati preliminari non auditati per l'intero anno 2024 e forniranno aggiornamenti sulle previsioni finanziarie per il 2025 e oltre.
Gli investitori possono pre-registrarsi per la chiamata dal vivo tramite un link di registrazione fornito. La presentazione sarà inoltre accessibile tramite webcast nella sezione 'Investitori' del sito web di Halozyme, con il materiale della presentazione disponibile 15 minuti prima della chiamata. Una registrazione della chiamata sarà resa disponibile successivamente.
Halozyme Therapeutics (NASDAQ: HALO) ha anunciado una próxima conferencia telefónica para inversores programada para el miércoles 8 de enero de 2025, a las 5:30 a.m. PT / 8:30 a.m. ET. Durante esta llamada, Dr. Helen Torley, Presidenta y CEO, y Nicole LaBrosse, CFO, presentarán los resultados preliminares no auditados para el año completo 2024 y proporcionarán orientación financiera actualizada para 2025 y más allá.
Los inversores pueden preinscribirse para la llamada en vivo a través de un enlace de registro proporcionado. La presentación también será accesible a través de un webcast en la sección de 'Inversores' del sitio web de Halozyme, con los materiales de presentación disponibles 15 minutos antes de la llamada. Se pondrá a disposición una grabación de la llamada después.
Halozyme Therapeutics (NASDAQ: HALO)는 2025년 1월 8일 수요일, 오전 5시 30분 PT / 오전 8시 30분 ET에 예정된 투자자 컨퍼런스 콜을 발표했습니다. 이 통화 중에 Dr. Helen Torley 사장 겸 CEO와 Nicole LaBrosse CFO가 2024년 전체에 대한 preliminary unaudited 결과를 발표하고 2025년 및 그 이후에 대한 업데이트된 재정 지침을 제공할 것입니다.
투자자들은 제공된 등록 링크를 통해 라이브 콜에 사전 등록할 수 있습니다. 발표 자료는 콜 시작 15분 전에 Halozyme 웹사이트의 '투자자' 섹션을 통해 웹캐스트로도 접근할 수 있습니다. 통화 녹음은 이후에 제공될 것입니다.
Halozyme Therapeutics (NASDAQ: HALO) a annoncé une prochaine conférence téléphonique pour les investisseurs prévue pour le mercredi 8 janvier 2025, à 5h30 PT / 8h30 ET. Lors de cet appel, Dr. Helen Torley, Présidente et PDG, et Nicole LaBrosse, CFO, présenteront les résultats préliminaires non audités de l'année entière 2024 et fourniront une mise à jour des prévisions financières pour 2025 et au-delà.
Les investisseurs peuvent se préinscrire pour l'appel en direct via un lien d'inscription fourni. La présentation sera également accessible par Webcast dans la section 'Investisseurs' du site Web de Halozyme, avec les documents de présentation disponibles 15 minutes avant l'appel. Un enregistrement de l'appel sera mis à disposition par la suite.
Halozyme Therapeutics (NASDAQ: HALO) hat eine bevorstehende Telefonkonferenz für Investoren angekündigt, die für Mittwoch, den 8. Januar 2025, um 5:30 Uhr PT / 8:30 Uhr ET geplant ist. Während dieses Anrufs werden Dr. Helen Torley, Präsidentin und CEO, und Nicole LaBrosse, CFO, die vorläufigen ungeprüften Ergebnisse für das gesamte Jahr 2024 präsentieren und aktualisierte Finanzleitlinien für 2025 und darüber hinaus bereitstellen.
Investoren können sich über einen bereitgestellten Anmeldelink für den Live-Anruf vorregistrieren. Die Präsentation wird auch über einen Webcast im Bereich 'Investoren' der Website von Halozyme zugänglich sein, wobei die Präsentationsmaterialien 15 Minuten vor dem Anruf verfügbar sein werden. Eine Aufzeichnung des Anrufs wird danach zur Verfügung gestellt.
- None.
- None.
On the call, Dr. Helen Torley, President and Chief Executive Officer, and Nicole LaBrosse, Chief Financial Officer, will provide preliminary unaudited full year 2024 results and updated 2025 and multi-year financial guidance.
Pre-registration of the live call can be accessed via link here: https://registrations.events/direct/Q4I871904593. The call will also be webcast live through the "Investors" section of Halozyme's corporate website and a recording will be made available following the close of the call. To access the webcast and presentation materials, which will be available 15 minutes before the call, please visit Halozyme.com.
About Halozyme
Halozyme is a biopharmaceutical company advancing disruptive solutions to improve patient experiences and outcomes for emerging and established therapies. As the innovators of ENHANZE® drug delivery technology with the proprietary enzyme rHuPH20, Halozyme's commercially-validated solution is used to facilitate the subcutaneous delivery of injected drugs and fluids, with the goal of improving the patient experience with rapid subcutaneous delivery and reduced treatment burden. Having touched more than 800,000 patient lives in post-marketing use in nine commercialized products across more than 100 global markets, Halozyme has licensed its ENHANZE® technology to leading pharmaceutical and biotechnology companies including Roche, Takeda, Pfizer, Janssen, AbbVie, Eli Lilly, Bristol-Myers Squibb, argenx, ViiV Healthcare, Chugai Pharmaceutical and Acumen Pharmaceuticals.
Halozyme also develops, manufactures and commercializes, for itself or with partners, drug-device combination products using its advanced auto-injector technologies that are designed to provide commercial or functional advantages such as improved convenience, reliability and tolerability, and enhanced patient comfort and adherence. The Company has two commercial proprietary products, Hylenex® and XYOSTED®, partnered commercial products and ongoing product development programs with Teva Pharmaceuticals and Idorsia Pharmaceuticals.
Halozyme is headquartered in
For more information visit www.halozyme.com and connect with us on LinkedIn and Twitter.
Contacts:
Tram Bui
VP, Investor Relations and Corporate Communications
609-359-3016
tbui@halozyme.com
Samantha Gaspar
Teneo
212-886-9356
samantha.gaspar@teneo.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/halozyme-to-host-investor-conference-call-to-provide-updated-2025-financial-guidance-302342725.html
SOURCE Halozyme Therapeutics, Inc.
FAQ
When is Halozyme's (HALO) investor conference call scheduled for January 2025?
What will be discussed in Halozyme's January 8, 2025 investor call?
Who will be presenting at Halozyme's January 2025 investor conference call?
How can investors access Halozyme's January 8, 2025 conference call?
When will the presentation materials for Halozyme's January 2025 investor call be available?
